Free tool
FAERS Monitor: Prempro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020527 or its brand name (Prempro, Estrogens, Conjugated, Medroxyprogesterone Acetate). Reports on generic versions are filed under their own applications.
Reports
23,488
Serious
19,848
85% of reports
Hospitalization
2,759
Death reported
648
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- breast cancer7,889
- breast cancer female5,791
- breast cancer metastatic1,505
- drug ineffective738
- cerebrovascular accident502
- depression478
- headache426
- anxiety418
- nausea414
- deep vein thrombosis397
- fatigue395
- hot flush388
- pain383
- insomnia380
- myocardial infarction378
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,602 |
| 2005 | 1,529 |
| 2006 | 1,384 |
| 2007 | 949 |
| 2008 | 1,913 |
| 2009 | 4,410 |
| 2010 | 5,905 |
| 2011 | 1,202 |
| 2012 | 754 |
| 2013 | 487 |
| 2014 | 363 |
| 2015 | 389 |
| 2016 | 399 |
| 2017 | 311 |
| 2018 | 237 |
| 2019 | 322 |
| 2020 | 371 |
| 2021 | 224 |
| 2022 | 259 |
| 2023 | 157 |
| 2024 | 132 |
| 2025 | 119 |
| 2026 | 68 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,030,671 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breast cancer femaleSignal | 5,791 | 247.5 | 241.1 | 1,115,140 |
| breast cancer metastaticSignal | 1,505 | 145.9 | 138.3 | 186,153 |
| breast cancerSignal | 7,889 | 82.7 | 81.1 | 585,463 |
| deep vein thrombosisSignal | 397 | 5.5 | 5.0 | 1,452 |
| hot flushSignal | 388 | 4.6 | 4.2 | 1,098 |
| cerebrovascular accidentSignal | 502 | 2.7 | 2.4 | 520 |
| myocardial infarction | 378 | 1.9 | 1.8 | 173 |
| depression | 478 | 1.9 | 1.7 | 199 |
| anxiety | 418 | 1.3 | 1.2 | 32 |
| insomnia | 380 | 1.3 | 1.2 | 23 |
| headache | 426 | 0.6 | 0.6 | 110 |
| pain | 383 | 0.6 | 0.5 | 138 |
| drug ineffective | 738 | 0.5 | 0.5 | 390 |
| nausea | 414 | 0.5 | 0.4 | 259 |
| fatigue | 395 | 0.5 | 0.4 | 269 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.